2017 ACVIM Forum Research Abstract Program

Prognostic factors identified on univariate analysis as significant for median progression free survival time and/or MST included cell size on FC, presence of lymphocytosis, presence of hypercalcemia, need for dose reduction, experiencing complete remission as best response to therapy, and completing CHOP. Further studies are needed to determine factors that may allow for further patient stratification to eventually modify therapy to improve outcome. Canine osteosarcoma (OSA) is a highly aggressive mesenchymal cancer accounting for 85% of canine bone tumors. OSA commonly arises in the long bones of large breed dogs, and 95% of patients are thought to have micrometastases at diagnosis. Standard of care treatment for canine OSA consists of amputation followed by chemotherapy, with median survival times ranging from 207 to 366 days. Development of metastatic disease limits longterm survival, with 9.7%-28% of patients alive two years from diagnosis. Treatment of macroscopic metastasis is unrewarding and given this, therapy is focused on prevention of metastatic disease.